{"id":"https://openalex.org/W3043311202","doi":"https://doi.org/10.1212/wnl.94.15_supplement.1557","title":"Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD): Safety, Tolerability, and Target Engagement (1557)","display_name":"Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD): Safety, Tolerability, and Target Engagement (1557)","publication_year":2020,"publication_date":"2020-04-14","ids":{"openalex":"https://openalex.org/W3043311202","doi":"https://doi.org/10.1212/wnl.94.15_supplement.1557","mag":"3043311202"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.94.15_supplement.1557","doi":"https://doi.org/10.1212/wnl.94.15_supplement.1557","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.94.15_supplement.1557","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090637756","display_name":"Michelle L. Mellion","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094323","display_name":"Fulcrum Therapeutics (United States)","ror":"https://ror.org/006f8jv23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle Mellion","raw_affiliation_strings":["Fulcrum Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fulcrum Therapeutics","institution_ids":["https://openalex.org/I4210094323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113492261","display_name":"Lucienne V. Ronco","orcid":"https://orcid.org/0000-0001-8045-3314","observed_orcids":["https://orcid.org/0000-0001-8045-3314"]},"institutions":[{"id":"https://openalex.org/I4210094323","display_name":"Fulcrum Therapeutics (United States)","ror":"https://ror.org/006f8jv23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lucienne Ronco","raw_affiliation_strings":["Fulcrum Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fulcrum Therapeutics","institution_ids":["https://openalex.org/I4210094323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065362371","display_name":"Lorin A. Thompson","orcid":"https://orcid.org/0000-0002-5600-3601","observed_orcids":["https://orcid.org/0000-0002-5600-3601"]},"institutions":[{"id":"https://openalex.org/I4210094323","display_name":"Fulcrum Therapeutics (United States)","ror":"https://ror.org/006f8jv23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lorin Thompson","raw_affiliation_strings":["Fulcrum Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fulcrum Therapeutics","institution_ids":["https://openalex.org/I4210094323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088182421","display_name":"Michelle Hage","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094323","display_name":"Fulcrum Therapeutics (United States)","ror":"https://ror.org/006f8jv23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle Hage","raw_affiliation_strings":["Fulcrum Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fulcrum Therapeutics","institution_ids":["https://openalex.org/I4210094323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086423313","display_name":"Sander Brooks","orcid":"https://orcid.org/0000-0003-3539-2908","observed_orcids":["https://orcid.org/0000-0003-3539-2908"]},"institutions":[{"id":"https://openalex.org/I4210133171","display_name":"Centre for Human Drug Research","ror":"https://ror.org/044hshx49","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210133171"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Sander Brooks","raw_affiliation_strings":["Centre for Human Drug Research (CHDR)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Human Drug Research (CHDR)","institution_ids":["https://openalex.org/I4210133171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067041210","display_name":"Emilie M.J. van Brummelen","orcid":"https://orcid.org/0000-0002-6526-4790","observed_orcids":["https://orcid.org/0000-0002-6526-4790"]},"institutions":[{"id":"https://openalex.org/I4210133171","display_name":"Centre for Human Drug Research","ror":"https://ror.org/044hshx49","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210133171"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Emilie van Brummelen","raw_affiliation_strings":["Centre for Human Drug Research (CHDR)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Human Drug Research (CHDR)","institution_ids":["https://openalex.org/I4210133171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034820865","display_name":"Lisa Pagan","orcid":"https://orcid.org/0000-0002-2064-7501","observed_orcids":["https://orcid.org/0000-0002-2064-7501"]},"institutions":[{"id":"https://openalex.org/I4210133171","display_name":"Centre for Human Drug Research","ror":"https://ror.org/044hshx49","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210133171"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Lisa Pagan","raw_affiliation_strings":["Centre for Human Drug Research (CHDR)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Human Drug Research (CHDR)","institution_ids":["https://openalex.org/I4210133171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056240427","display_name":"Umesh A. Badrising","orcid":"https://orcid.org/0000-0003-0146-2664","observed_orcids":["https://orcid.org/0000-0003-0146-2664"]},"institutions":[{"id":"https://openalex.org/I2800006345","display_name":"Leiden University Medical Center","ror":"https://ror.org/05xvt9f17","country_code":"NL","type":"funder","lineage":["https://openalex.org/I2800006345"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Umesh Badrising","raw_affiliation_strings":["Leiden University Medical Centre"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leiden University Medical Centre","institution_ids":["https://openalex.org/I2800006345"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013002662","display_name":"Shane R. Raines","orcid":"https://orcid.org/0009-0007-0637-8476","observed_orcids":["https://orcid.org/0009-0007-0637-8476"]},"institutions":[{"id":"https://openalex.org/I4210094323","display_name":"Fulcrum Therapeutics (United States)","ror":"https://ror.org/006f8jv23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shane Raines","raw_affiliation_strings":["Fulcrum Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fulcrum Therapeutics","institution_ids":["https://openalex.org/I4210094323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078628655","display_name":"William G. Tracewell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094323","display_name":"Fulcrum Therapeutics (United States)","ror":"https://ror.org/006f8jv23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Tracewell","raw_affiliation_strings":["Fulcrum Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fulcrum Therapeutics","institution_ids":["https://openalex.org/I4210094323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072004949","display_name":"Baziel G.M. van Engelen","orcid":"https://orcid.org/0000-0001-9867-9047","observed_orcids":["https://orcid.org/0000-0001-9867-9047"]},"institutions":[{"id":"https://openalex.org/I2802934949","display_name":"Radboud University Medical Center","ror":"https://ror.org/05wg1m734","country_code":"NL","type":"funder","lineage":["https://openalex.org/I2802934949"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Baziel van Engelen","raw_affiliation_strings":["Radboud University Nijmegen Medical Centre"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Radboud University Nijmegen Medical Centre","institution_ids":["https://openalex.org/I2802934949"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016359089","display_name":"Geert Jan Groeneveld","orcid":"https://orcid.org/0000-0002-4655-6667","observed_orcids":["https://orcid.org/0000-0002-4655-6667"]},"institutions":[{"id":"https://openalex.org/I4210133171","display_name":"Centre for Human Drug Research","ror":"https://ror.org/044hshx49","country_code":"NL","type":"facility","lineage":["https://openalex.org/I4210133171"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Geert-Jan Groeneveld","raw_affiliation_strings":["Centre for Human Drug Research (CHDR)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Human Drug Research (CHDR)","institution_ids":["https://openalex.org/I4210133171"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088163706","display_name":"Diego Cadavid","orcid":"https://orcid.org/0000-0002-5361-3834","observed_orcids":["https://orcid.org/0000-0002-5361-3834"]},"institutions":[{"id":"https://openalex.org/I4210094323","display_name":"Fulcrum Therapeutics (United States)","ror":"https://ror.org/006f8jv23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210094323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diego Cadavid","raw_affiliation_strings":["Fulcrum Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fulcrum Therapeutics","institution_ids":["https://openalex.org/I4210094323"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2433,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.45042532,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"94","issue":"15_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10441","display_name":"Muscle Physiology and Disorders","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10441","display_name":"Muscle Physiology and Disorders","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12400","display_name":"Neurogenetic and Muscular Disorders Research","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10855","display_name":"Amyotrophic Lateral Sclerosis Research","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/losmapimod","display_name":"losmapimod","score":1.0},{"id":"https://openalex.org/keywords/facioscapulohumeral-muscular-dystrophy","display_name":"facioscapulohumeral muscular dystrophy","score":0.996999979019165},{"id":"https://openalex.org/keywords/facioscapulohumeral-muscular-dystrophy-type-1","display_name":"FSHD1","score":0.8579999804496765},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.671999990940094},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9990000128746033},{"id":"https://openalex.org/keywords/target-engagement","display_name":"target engagement","score":0.9860000014305115},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.859000027179718}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8738862872123718},{"id":"https://openalex.org/C2779981540","wikidata":"https://www.wikidata.org/wiki/Q1399182","display_name":"Facioscapulohumeral muscular dystrophy","level":3,"score":0.8343650102615356},{"id":"https://openalex.org/C2779030066","wikidata":"https://www.wikidata.org/wiki/Q1137767","display_name":"Muscular dystrophy","level":2,"score":0.6309725046157837},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.630120038986206},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5421060919761658},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.26674696803092957},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.21889448165893555}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.94.15_supplement.1557","doi":"https://doi.org/10.1212/wnl.94.15_supplement.1557","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.94.15_supplement.1557","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8399999737739563}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389460747","https://openalex.org/W2976929844","https://openalex.org/W4236256126","https://openalex.org/W4389366487","https://openalex.org/W4399696651","https://openalex.org/W4206583037","https://openalex.org/W3159336201","https://openalex.org/W4389366472","https://openalex.org/W4205942049","https://openalex.org/W4394800606"],"abstract_inverted_index":{"Objective:":[0],"Investigate":[1],"safety,":[2],"tolerability,":[3],"pharmacokinetics":[4],"(PK),":[5],"and":[6,16,45,139,148,156,161,168,181,189,200,207,211,223,245,261,267,320,364,546,552],"target":[7,247],"engagement":[8,248],"(TE)":[9],"of":[10,27,54,65,82,100,197,234,398,400],"losmapimod":[11,83,108,124],"in":[12,33,42,166,195,220,241,265,330,336,352,424,430,446],"healthy":[13],"volunteers":[14],"(HV)":[15,199,210],"FSHD1":[17,102],"patients.":[18],"Background:":[19],"FSHD":[20,190],"is":[21,48],"caused":[22],"by":[23,159,272,278,561],"the":[24,28,62,286,396],"aberrant":[25],"expression":[26],"homeobox":[29],"transcription":[30],"factor":[31],"DUX4":[32,36,60,280],"skeletal":[34],"muscle.":[35,169],"activates":[37],"a":[38,49,70,229,309,377,459,489,528,573,594,628],"transcriptional":[39],"program":[40],"resulting":[41],"muscle":[43,153,221,232,268],"loss":[44],"disability.":[46],"Losmapimod":[47,253],"selective":[50],"small":[51],"molecule":[52],"inhibitor":[53],"p38\u03b1/\u03b2":[55],"being":[56],"developed":[57],"to":[58,78,105,231,275,503,510,516,610,616],"reduce":[59],"expression,":[61],"root":[63],"cause":[64],"FSHD.":[66],"Design/Methods:":[67],"This":[68],"was":[69,239,254,340,434],"three-part":[71],"study.":[72],"Part":[73,96,121],"A:":[74],"10":[75],"HV":[76,188],"randomized":[77,104],"single":[79],"oral":[80],"doses":[81],"(7.5":[84],"mg":[85,110,114,126,288],"then":[86],"15":[87,113,125,216,250,287],"mg;":[88],"n=8)":[89],"or":[90,112,314,382,410,464,494,533,578,599,633],"placebo":[91,106],"(both":[92],"dosing":[93],"periods;":[94],"n=2).":[95],"B:":[97],"Parallel-group":[98],"study":[99],"losmapimod15":[101],"patients":[103],"(n=3),":[107],"7.5":[109,205],"(n=6)":[111,115],"twice":[116,128],"daily":[117,129],"for":[118,130,204,215,305,373,393,455,485,524,544,558,569,590,624],"14":[119,131],"days.":[120,132],"C:":[122],"Open-label":[123],"(n=5)":[127],"Muscle":[133],"biopsies":[134],"were":[135,164,179,185,226],"performed":[136],"at":[137,249,269],"baseline":[138],"during":[140],"treatment,":[141],"targeting":[142],"MRI":[143],"normal":[144],"appearing":[145],"(Part":[146,151],"B)":[147],"STIR":[149],"+":[150],"C)":[152],"tissue.":[154],"PK":[155,183],"TE,":[157],"measured":[158],"phosphorylated":[160],"total":[162],"HSP27,":[163],"assessed":[165],"blood":[167,196,242],"Results:":[170],"Preliminary":[171],"blinded":[172],"analysis":[173],"showed":[174],"that":[175],"adverse":[176],"events":[177],"(AE)":[178],"mild":[180],"self-limited.":[182],"profiles":[184],"similar":[186],"between":[187],"patients:":[191],"mean":[192],"C":[193],"max":[194],"36.6":[198],"40.9":[201],"ng/mL":[202,209,213],"(FSHD)":[203],"mg,":[206],"74.6":[208],"85.0":[212],"(FSHD1)":[214],"mg.":[217,251],"Dose-dependent":[218,237],"concentrations":[219,270],"(42.1":[222],"63.6":[224],"ng/g)":[225],"observed,":[227],"with":[228,243,257,317,385,467,497,536,581,602,636],"plasma":[230,266],"ratio":[233],"approximately":[235],"1:1.":[236],"TE":[238],"observed":[240],"robust":[244],"sustained":[246],"Conclusions:":[252],"well":[255],"tolerated":[256],"no":[258],"SAEs":[259],"reported":[260],"achieved":[262],"dose-dependent":[263],"exposure":[264],"predicted":[271],"pre-clinical":[273],"models":[274],"provide":[276],"efficacy":[277],"reducing":[279],"activity.":[281],"These":[282],"results":[283],"support":[284,360,475,644],"advancing":[285],"dose":[289],"into":[290],"Phase":[291],"2.":[292],"Final":[293],"data":[294],"will":[295],"be":[296],"presented.":[297],"Disclosure:":[298],"Dr.":[299,323,338,345,355,367,388,403,417,432,439,449,470,479,505,512,518,537,563,584,605,612,618,639],"Mellion":[300,324,339,346,356],"has":[301,357,369,390,405,451,472,481,501,508,514,520,565,586,608,614,620,641],"received":[302,358,370,391,406,452,473,482,521,542,566,587,621,642],"personal":[303,371,453,483,522,567,588,622],"compensation":[304,372,392,454,484,523,543,554,568,589,623],"consulting,":[306,374,456,486,525,570,591,625],"serving":[307,375,394,457,487,526,571,592,626],"on":[308,376,395,458,488,527,572,593,627],"scientific":[310,378,460,490,529,574,595,629],"advisory":[311,379,461,491,530,575,596,630],"board,":[312,380,462,492,531,576,597,631],"speaking,":[313,381,463,493,532,577,598,632],"other":[315,383,465,495,534,579,600,634],"activities":[316,384,466,496,535,580,601,635],"Fulcrum":[318,362,386,401,415,425,447,468,477,498,582,603,637,646],"Therapeutics":[319,363,426],"Vertex":[321,331,353,365],"Pharmaceuticals.":[322,354,366],"holds":[325,347,419,441],"stock":[326,328,348,350,420,422,442,444],"and/or":[327,349,421,443],"options":[329,351,423,445],"Pharmaceuticals":[332],"which":[333,337,427,431],"sponsored":[334,428],"research":[335,359,429,474,643],"involved":[341,435],"as":[342,436],"an":[343,437],"investigator.":[344,438],"from":[361,414,476,550,555,645],"Ronco":[368,389,404,418,433,440],"Therapeutics.":[387,402,416,448,469,478,583,638,647],"Board":[397],"Directors":[399],"royalty,":[407],"license":[408],"fees,":[409],"contractual":[411],"rights":[412],"payments":[413],"Thompson":[450,471],"Hage":[480],"Therapeutics.Dr.":[499],"Brooks":[500],"nothing":[502,509,515,609,615],"disclose.":[504,511,517,611,617],"van":[506,606],"Brummelen":[507],"Pagan":[513],"Badrising":[519],"Badrising\u2019s":[538],"institution":[539],"(The":[540],"LUMC)":[541],"consultancy":[545,553],"clinical":[547],"trial":[548],"fees":[549],"Novartis":[551],"Argen":[556],"X":[557],"work":[559],"done":[560],"U.B.":[562],"Raines":[564],"Tracewell":[585],"Therapuetics.":[604],"Engelen":[607],"Groeneveld":[613],"Cadavid":[619,640]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2020-07-23T00:00:00"}